Form 8-K - Current report:
SEC Accession No. 0001683168-25-002396
Filing Date
2025-04-10
Accepted
2025-04-10 08:00:09
Documents
15
Period of Report
2025-04-08
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K xenetic_8k.htm   iXBRL 8-K 30513
2 LETTER FROM MARCUM LLP DATED APRIL 8, 2025 xenetic_ex1601.htm EX-16.1 1436
3 GRAPHIC image_001.jpg GRAPHIC 5913
  Complete submission text file 0001683168-25-002396.txt   213409

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE xbio-20250408.xsd EX-101.SCH 3020
5 XBRL LABEL FILE xbio-20250408_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE xbio-20250408_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_8k_htm.xml XML 3572
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37937 | Film No.: 25826522
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)